Press Room

DDF - 15th Global Drug Delivery & Formulation Summit

Start
Tuesday, May 21, 2024
End
Thursday, May 23, 2024
Location: Berlin, Germany
Booth Number: Table # 16
DDF_ɫAV_2024

ɫAV will be exhibiting at the Global DDF Summit, the premier drug delivery, formulation and device development event from May 21-23 in Berlin.

Don’t miss the chance to speak with our experts – Table No. 16 – and learn how our extensive knowledge and experience can support your project from early stages of development to commercialization.

schedule a meeting

On May 22, don’t miss our Technology & Innovation session

Manufacturing Amorphous Solid Dispersions for Continuous Direct Compression: Streamlining End-to-End Formulation and Process Development

This presentation will provide an end-to-end overview of an amorphous solid dispersion (ASD) development approach focusing not only on selecting the best excipients (including alternative excipients to broaden the formulation landscape) but also how to convert it into a commercially viable process as a final oral dosage form by Continuous Direct Compression. Using a streamlined approach and proprietary technologies, an overview of how to expedite the screening phase and process development with minimal API requirements will be given. This not only shortens the time to Phase I/IND by accelerating formulation and process development but also improves supply chain flexibility and opens new possibilities for Lifecycle Management. To deliver a successful ASD-based oral dosage form by Continuous Direct Compression, the following aspects must be considered: 1) high-throughput screening, 2) digital twins and scale-up models, and 3) integrated ASD and tablet formulation / process development. ɫAV case studies on enabling Continuous Direct Compression of ASDs will be discussed.

Key learnings:

  • Unleashing full potential of ASDs requires integrated optimization of formulations and processes, leveraging integrated high throughput formulation platforms (ASD-HIPROS) to reduce time to Phase I/IND.
  • Engineered Spray Dried powders are amenable to Continuous Direct Compression, which greatly simplifies drug product process trains and improves supply chain flexibility / Lifecycle Management options.

and learn how we can maximize the potential of your ASD development and streamline your drug product processes.

Webinar Series Spray Drying Speakers - Ines Ramos | ɫAV
Webinar Series Spray Drying Speakers - Pedro Monteiro | ɫAV
Inês Ramos, Ph.D.
R&D Manager
Oral Drug Product Development - Formulation Group
Pedro Monteiro, M.Sc.
R&D Senior Scientist
Oral Drug Product Development - Formulation Group

Find more about

Get to know more about ASD-HIPROS, the most advanced and accurate screening platform able to identify the most efficient and stable Amorphous Solid Dispersion formulations by Spray Drying.

Get to know more about Continuous Tableting at ɫAV.

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024